TAMPA, Fla.–(BUSINESS WIRE)–Neutra
Corp. (OTCQB: NTRR) and joint venture partner Oceanview Health
Services Ltd. are preparing to promote and market a new line of
cannabis-infused topical products, and the latest data shows that they
could soon receive a warm welcome in the nation’s newest medical
Press reports that infused products and concentrates such as
topicals accounted for 11
percent of sales in Illinois’ dispensaries last month. That number
is being called a solid start by industry watchers, and likely the
beginning of much more to follow. In Washington State, topicals and
other infused products accounted for a quarter of total cannabis sales
in the third quarter of 2015, according to a report by research firm BDS
“The first dispensaries in the state opened last November, but only a
very small number of cannabis cultivators in Illinois are currently
making infused products,” said NTRR CEO Chris Brown. “We see that as a
major opportunity. As patients become better exposed and more familiar
with topicals, we’re confident that they will begin to command an even
higher share of total sales there.”
Last month, NTRR partner Oceanview Health Services Ltd. revealed the
debut products that will comprise its innovative BeKind Topicals line
set to hit dispensary shelves this year. The initial lineup will include
a pain cream and a topical spray, both infused with different cannabis
strains. The new products will be intended for the treatment of
arthritis, muscle soreness, nerve pain and other health issues in a
discrete and reliable manner. Once they are proven successful, plans
call for exploring new opportunities to license the formulas and brand
in areas where cannabis use is legal.
In 2016, NTRR plans to deliver many new offerings for cannabis producers
and consumers alike as the regulated cannabis industry continues to
swell in the United States, Canada and beyond. For more information on
the company’s mission, please visit http://neutrainc.com/investors.
About Neutra Corp.
Neutra Corp. is a healthy lifestyle company that specializes in the
development and marketing of natural wellness solutions, including
cannabis-related products. By providing a variety of new technologies
designed to ensure safer, more reliable access to cannabis in approved
markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals
(OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp.
(OTCBB: EDXC), delivering technological advancements in the cultivation
and processing of cannabis in approved markets. For investing
information and performance data, please visit www.neutrainc.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This news release contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words “believes,”
“expects,” “anticipate” or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the Company to differ materially from those expressed or implied by
such forward-looking statements. In addition, description of anyone’s
past success, either financial or strategic, is no guarantee of success.
This news release speaks as of the date first set forth above and the
Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Chris Brown, 813-367-2041
President and CEO